Long Run Wealth Advisors LLC Has $1.38 Million Stake in Pfizer Inc. (NYSE:PFE)

Long Run Wealth Advisors LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 12.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 52,001 shares of the biopharmaceutical company’s stock after buying an additional 5,916 shares during the period. Long Run Wealth Advisors LLC’s holdings in Pfizer were worth $1,380,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Centennial Wealth Advisory LLC increased its stake in Pfizer by 11.3% in the fourth quarter. Centennial Wealth Advisory LLC now owns 24,618 shares of the biopharmaceutical company’s stock valued at $653,000 after acquiring an additional 2,490 shares during the last quarter. Benchmark Financial Wealth Advisors LLC increased its stake in Pfizer by 2.8% in the fourth quarter. Benchmark Financial Wealth Advisors LLC now owns 15,682 shares of the biopharmaceutical company’s stock valued at $416,000 after acquiring an additional 434 shares during the last quarter. Onyx Bridge Wealth Group LLC increased its stake in Pfizer by 7.4% in the fourth quarter. Onyx Bridge Wealth Group LLC now owns 33,214 shares of the biopharmaceutical company’s stock valued at $881,000 after acquiring an additional 2,290 shares during the last quarter. Inman Jager Wealth Management LLC bought a new position in Pfizer in the fourth quarter valued at approximately $607,000. Finally, Tyche Wealth Partners LLC grew its stake in shares of Pfizer by 23.1% during the fourth quarter. Tyche Wealth Partners LLC now owns 25,860 shares of the biopharmaceutical company’s stock worth $686,000 after buying an additional 4,859 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.46 on Thursday. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The stock has a market cap of $149.94 billion, a price-to-earnings ratio of 35.76, a PEG ratio of 0.66 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm’s 50-day simple moving average is $26.27 and its 200 day simple moving average is $27.79.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the firm earned $0.10 EPS. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.50%. Pfizer’s dividend payout ratio (DPR) is 232.44%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PFE. Sanford C. Bernstein began coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.